Frequently Asked Questions

June 2015 FAQs

What is the evidence to support twice-daily dosing of insulin glargine?

What is the rationale and significance of the FDA’s new guidance for abuse-deterrent opioids?

What should healthcare providers know about PCSK9 inhibitors, the new class of cholesterol-lowering medications?

May 2015 FAQs

What evidence supports the efficacy of the new antibiotic, ceftazidime/avibactam (Avycaz)?

What should healthcare providers know about the recent measles outbreak in the United States?

What are the current recommendations for managing patients initiating non-VKA oral anticoagulants (NOACs) after receiving thrombolytic therapies for pulmonary embolism?

April 2015 FAQs

What drugs should be avoided in myasthenia gravis?

Is normal saline or heparin preferred as a catheter flush solution?

Should warfarin be resumed after gastrointestinal bleeding, and if so – when?

March 2015 FAQs

What are the new guidelines for the pharmacological management of obesity??

What information is available on the use of peramivir for treatment of influenza?

What data supports the use of new oral anticoagulants in special populations (hepatic impairment, obesity, pregnancy, lactation, and pediatrics)?

February 2015 FAQs

What are the new recommendations for direct-acting antivirals for treatment of hepatitis C virus?

What is the Evidence for Use of Inhaled Epoprostenol?

What vaccines should be administered to adult, splenectomized, patients?

January 2015 FAQs

What is the Evidence for Use of Bronchodilators in Bronchiolitis?

What are Current Recommendations for Treatment of Drug Extravasation?

Is Vancomycin Therapy with Targeted Troughs Between 15 and 20 mg/L Associated with an Increased Risk of Nephrotoxicity?


FAQs 2014

FAQs 2013

FAQs 2012

FAQs 2011

FAQs 2010